Fragile X Syndrome Pipeline constitutes 10+ key companies continuously working towards developing 12+ Fragile X Syndrome treatment therapies, analyzes DelveInsight.
Fragile X Syndrome Overview:
Fragile X syndrome (FXS), also known as Martin-Bell syndrome, is a genetic condition caused by a mutation in the *FMR1* gene, which results in the absence of the FMRP protein critical for brain development. It is the most common inherited cause of intellectual disability and a significant genetic contributor to autism spectrum disorder. Physically, individuals may present with distinctive features such as a long face, large ears, and hyperflexible joints.
FXS is diagnosed through DNA testing from a blood sample, which can also reveal related genetic risks. Because of the potential impact on family members, genetic counseling is recommended before testing. While there is no cure, management of FXS centers on early intervention and supportive therapies including speech, occupational, behavioral, and sensory integration therapy. Psychiatric care and nutritional guidance are also important, as individuals may face challenges such as obesity, anxiety, depression, or self-injury. Medications like stimulants or antidepressants can help manage behavioral symptoms, though their use varies by age group.
Request for a detailed insights report on Fragile X Syndrome pipeline insights @ https://www.delveinsight.com/report-store/fragile-x-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
“Fragile X Syndrome Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Fragile X Syndrome Therapeutics Market.
Key Takeaways from the Fragile X Syndrome Pipeline Report
DelveInsight’s Fragile X Syndrome pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Fragile X Syndrome treatment.
In March 2022, the European Commission granted orphan drug designation to Zygel, a cannabidiol (CBD) transdermal gel developed by Zynerba Pharmaceuticals, for addressing behavioral symptoms in individuals with Fragile X Syndrome.
In February 2022, Ovid Therapeutics entered into an option agreement with Healx for the exclusive licensing of gaboxadol (OV101). Under this agreement, Healx acquired the option to develop and commercialize gaboxadol (OV101). Healx announced plans to explore the compound as part of a potential combination therapy for Fragile X Syndrome, as well as for other potential indications.
Key Fragile X Syndrome companies such as Zynerba Pharmaceuticals, Inc., Tetra Discovery Partners, Nova Mentis Life Science Corp, Neuren Pharmaceuticals Limited, Tetra Discovery Partners, and others are evaluating new drugs for Fragile X Syndrome to improve the treatment landscape.
Promising Fragile X Syndrome pipeline therapies in various stages of development include ZYN002, NNZ-2566, and others.
Fragile X Syndrome Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Fragile X Syndrome Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fragile X Syndrome treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Fragile X Syndrome market.
Download our free sample page report on Fragile X Syndrome pipeline insights
Fragile X Syndrome Emerging Drugs
ZYN002: Zynerba Pharmaceuticals, Inc.
NNZ-2566: Neurons Pharmaceuticals Limited
Fragile X Syndrome Companies
Approximately 10 or more prominent companies are actively developing therapies for Fragile X Syndrome. Among them, Zynerba Pharmaceuticals and other organizations have drug candidates currently in the most advanced stage of development, specifically Phase III clinical trials.
DelveInsight’s report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Fragile X Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Fragile X Syndrome Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Fragile X Syndrome Therapies and Key Companies: Fragile X Syndrome Clinical Trials and advancements
Fragile X Syndrome Pipeline Therapeutic Assessment
• Fragile X Syndrome Assessment by Product Type
• Fragile X Syndrome By Stage
• Fragile X Syndrome Assessment by Route of Administration
• Fragile X Syndrome Assessment by Molecule Type
Download Fragile X Syndrome Sample report to know in detail about the Fragile X Syndrome treatment market @ Fragile X Syndrome Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Fragile X Syndrome Current Treatment Patterns
4. Fragile X Syndrome – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Fragile X Syndrome Late-Stage Products (Phase-III)
7. Fragile X Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fragile X Syndrome Discontinued Products
13. Fragile X Syndrome Product Profiles
14. Fragile X Syndrome Key Companies
15. Fragile X Syndrome Key Products
16. Dormant and Discontinued Products
17. Fragile X Syndrome Unmet Needs
18. Fragile X Syndrome Future Perspectives
19. Fragile X Syndrome Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Fragile X Syndrome Pipeline Reports Offerings
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
